<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240704</url>
  </required_header>
  <id_info>
    <org_study_id>CJBH492A12101</org_study_id>
    <nct_id>NCT04240704</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics
      (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">May 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of dose limiting toxicities (DLTs)</measure>
    <time_frame>32 months</time_frame>
    <description>A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value that occurs during the first cycle of treatment with JBH492 and meets any of the protocol specified criteria, unless incontrovertibly related to underlying disease, intercurrent illness or concomitant medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events (AEs)</measure>
    <time_frame>32 months</time_frame>
    <description>An adverse event ( treatment emergent) is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient's signed informed consent has been obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of Serious Adverse Events (SAEs)</measure>
    <time_frame>32 months</time_frame>
    <description>A Serious adverse event (SAE) is defined as one of the following:
Is fatal or life-threatening
Results in persistent or significant disability/incapacity
Constitutes a congenital anomaly/birth defect
Is medically significant
Requires inpatient hospitalization or prolongation of existing hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with dose interruptions</measure>
    <time_frame>32 months</time_frame>
    <description>Tolerability measured by the number of subjects who have interruptions of study treatment and reason for interruptions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with dose reductions</measure>
    <time_frame>32 months</time_frame>
    <description>Tolerability measured by the number of subjects who have reductions of study treatment and reason for reductions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>32 months</time_frame>
    <description>Tolerability measured by the dose intensity of study drug, Relative Dose intensity for subjects with non-zero duration of exposure is computed as the ratio of dose intensity and planned dose intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>32 months</time_frame>
    <description>The overall response rate (ORR), defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR), as per local review and according to the iwCLL guideline (CLL) or Lugano Classification (NHL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>32 months</time_frame>
    <description>The best overall response (BOR) is the best reponse recorded in a patient from the start of treatment until disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>32 months</time_frame>
    <description>The time between the date of first documented response (CR or PR) and the date of first documented progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>32 months</time_frame>
    <description>PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter AUClast</measure>
    <time_frame>32 months</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) of JBH492 from time zero to the last measurable concentration sampling time (tlast) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUCinf</measure>
    <time_frame>32 months</time_frame>
    <description>The AUC from time zero to infinity (mass × time × volume-1) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter AUCtau</measure>
    <time_frame>32 months</time_frame>
    <description>The AUC calculated to the end of a dosing interval (tau) (mass × time × volume-1) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Cmax and Cmin</measure>
    <time_frame>32 months</time_frame>
    <description>The maximum (peak) and minimum observed serum drug concentration (mass × volume-1) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter Tmax</measure>
    <time_frame>32 months</time_frame>
    <description>The time to reach maximum (peak) serum drug concentration (time) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter T1/2</measure>
    <time_frame>32 months</time_frame>
    <description>The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve (time) for four analytes (total antibody, total antibody-drug-conjugate, DM4, sDM4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-JBH492 antibodies</measure>
    <time_frame>32 months</time_frame>
    <description>Number of subjects with anti-JBH492 antibodies (Anti-Drug Antibodies)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Hodgkins Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>JBH492 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JBH492</intervention_name>
    <description>Anti-CCR7 antibody-drug conjugate (ADC)</description>
    <arm_group_label>JBH492 single agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients with CLL:

        • Confirmed diagnosis of chronic lymphocytic leukemia (CLL)

        For patients with NHL:

          -  Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL).

          -  Must have a site of disease amenable to biopsy, and be suitable and willing to undergo
             study required biopsies at screening and during therapy.

        Exclusion Criteria, applicable to both CLL and NHL:

          -  History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs,
             monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable
             to tolerate immunoglobulin/monoclonal antibody administration

          -  Any prior history of treatment with maytansine (DM1 or DM4)-based ADC

          -  Known intolerance to a maytansinoid

          -  Patients with any active or chronic corneal disorders

          -  Patients who have any other condition that precludes monitoring of the retina or
             fundus

          -  Patients with active CNS involvement are excluded, except if the CNS involvement has
             been effectively treated and provided that local treatment was &gt; 4 weeks before
             enrollment. Patients that have been effectively treated for CNS disease and are stable
             under systemic therapy may be enrolled provided all other inclusion and exclusion
             criteria are met.

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Known history of Human Immunodeficiency Virus (HIV) infection

          -  Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Gallagher</last_name>
      <phone>480-342-2545</phone>
      <email>Gallagher.Deborah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Allison Rosenthal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Newton</last_name>
      <phone>507-538-2155</phone>
      <email>Newton.Jennifer@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Nowakowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Gauger</last_name>
      <phone>414-805-5249</phone>
      <email>kgauger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Fenske</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>NHL</keyword>
  <keyword>CCR7</keyword>
  <keyword>JBH492</keyword>
  <keyword>ADC</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Non-Hodgkins Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

